La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Genprex a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Genprex..

Genprex (NASDAQ:GNPX) Azioni, Catena delle Opzioni

Genprex

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

Genprex Inc

Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) will release earnings results for the first quarter, before the <a href="https://www.benzinga.com/quote/ROP/earnings">opening bell on Monday, April 28.</a>
Analysts expect the Sarasota, Florida-based company to report quarterly earnings at $4.74 per share, up from $4.41 per share in the year-ago period. Roper Technologies projects to report quarterly revenue at $1.88 billion, compared to $1.68 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On March 24, Roper Technologies disclosed a deal to acquire CentralReach from Insight Partners for a net purchase price of around $1.65 billion.
Roper Technologies shares fell 0.4% to close at $557.70 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/rop/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>JP Morgan analyst Stephen Tusa maintained a Neutral rating and cut the price target from $558 to $465 on April 8, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Brad Reback initiated coverage on the stock with a Buy rating and a price target of $685 on March 27, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Oppenheimer analyst Christopher Glynn maintained an Outperform rating and raised the price target from $630 to $640 on Jan. 31, 2025. This analyst has an accuracy rate of 77%.</li>
<li>Raymond James analyst Brian Gesuale reiterated a Strong Buy rating and increased the price target from $620 to $655 on Jan. 31, 2025. This analyst has an accuracy rate of 74%.</li>
<li>Barclays analyst Julian Mitchell maintained an Underweight rating and cut the price target from $569 to $562 on Jan. 8, 2025. This analyst has an accuracy rate of 72%.</li>
</ul>
Considering buying ROP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-1024x587.png" alt="" class="wp-image-890254" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183-768x440.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28031822/image-183.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Earnings

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

Roper Technologies Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

<ul>
<li>TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete response rate in BCG-Unresponsive patients</li>
<li>TARA-002 demonstrates 76% complete response rate at any time and 43% 12-month landmark complete response rate in BCG-Naïve patients</li>
<li>Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events</li>
<li>On track to present updated interim data from approximately 25 six-month evaluable BCG-Unresponsive patients by the end of 2025</li>
<li>Company to host conference call and webcast on Monday, April 28, 2025, at 8:30 a.m. ET</li>
</ul>

TARA

Reported Saturday, Protara Therapeutics Shares Interim Results Highlighting Durable Clinical Responses With TARA-002 In High-Risk NMIBC

The authorities initially prioritized vaccination of adults aged 65 and over, especially those with comorbidities. On April 25, the French health authorities decided to suspend the use of IXCHIQ&#xAE; in persons aged 65 years and older pending further investigation. This is a response to an ongoing investigation of three cases of SAEs resulting in hospitalization, including one death, after vaccination with IXCHIQ&#xAE; among people in La Reunion. The three individuals who were hospitalized were over 80 years old and had pre-existing comorbidities3. These SAEs were reported through the pharmacovigilance system set up by the French health authorities, and causality has not been definitively established. The HAS maintains its current recommendation for IXCHIQ&#xAE; for people aged 18 to 64 years old as part of the ongoing vaccination campaign.

VALN

Reported Saturday, Valneva Provides Update On IXCHIQ Chikungunya Vaccine Use Following HAS Recommendation And Safety Investigation

<ul>
<li>Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) regimen compared to SOC alone</li>
<li>Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in more than 30 years</li>
<li>Results have been shared with global health authorities to support potential regulatory filings</li>
</ul>

Reported Saturday, Pfizer's Sasanlimab Combination Therapy Shows Strong Event-Free Survival Gains In High-Risk Non-Muscle Invasive Bladder Cancer

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy
95 percent progression-free survival rate at 9-months signals the promise of TAR-200 in this high-risk patient population

Reported Saturday, Johnson & Johnson's TAR-200 Monotherapy Demonstrates Strong Early Efficacy In BCG-Unresponsive Bladder Cancer, Achieving Over 80% Disease-Free Survival

<ul>
<li>Robust 24-month complete response rate of 42.3% by K-M for cretostimogene monotherapy in BOND-003 Cohort C</li>
<li>58.3% of patients showed durable complete responses by K-M at 24 months</li>
<li>97.3% of all treated patients remained free from progression to MIBC at 24 month</li>
<li>91.6% of responders remained cystectomy-free at 24 month</li>
<li>No Grade 3 or greater treatment-related adverse events or deaths reported</li>
<li>Strong initial Cohort P data reported 90.5% high-grade recurrence-free survival at 3 and 9 months by K-M</li>
<li>Company will host a conference call and webcast at 8 a.m. EDT on Monday, April 28, 2025</li>
</ul>

CGON

Reported Saturday, CG Oncology Reports Durability In BOND-003 Cohort C And Encouraging Early Results In Cohort P For Cretostimogene Grenadenorepvec

A man has become the first non-verbal, as well as only the third person ever, to receive a Neuralink Brain-Chip Interface (BCI) implant.
What Happened: Author Bradford G Smith suffers from ALS or Amyotrophic Lateral Sclerosis, a very rare nervous system disease that severely impacts motor functions. Smith released a video on the social media platform X to share the update on Sunday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I am the 3rd person in the world to receive the <a href="https://twitter.com/neuralink?ref_src=twsrc%5Etfw">@Neuralink</a> brain implant. 1st with ALS. 1st Nonverbal. I am typing this with my brain. It is my primary communication. Ask me anything! I will answer at least all verified users! Thank you <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a>! <a href="https://t.co/bxYO3SBfA2">pic.twitter.com/bxYO3SBfA2</a>
&mdash; Bradford G Smith (Brad) (@ALScyborg) <a href="https://twitter.com/ALScyborg/status/1916630186382291242?ref_src=twsrc%5Etfw">April 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Smith says that he uses the Neuralink implant to control the cursor on his laptop as well as Grok AI to create a clone of his own voice to speak. The video Smith shared was also edited by the BCI chip.
Why It Matters: The news comes as Elon Musk has touted his Neuralink BCI as technology that will help completely <a href="https://www.benzinga.com/general/biotech/25/04/44892867/elon-musk-says-neuralink-will-help-blind-people-see-again-will-exceed-the-best-human-eyes">blind people see again</a>, the billionaire shared.&nbsp;&nbsp;
Musk also reiterated that robots would <a href="https://www.benzinga.com/25/04/45031447/elon-musk-says-the-best-human-surgeons-have-just-five-years-before-robots-overtake-them-reveals-instance-when-neuralink-had-to-use-a-robot-for-task-impossible-for-a-human">outperform human surgeons</a> in almost 5 years. He said Neuralink "had to use a robot for the brain-computer electrode insertion, as it was impossible for a human to achieve the required speed and precision."
Elsewhere, Neuralink is also eyeing an<a href="https://www.benzinga.com/general/biotech/25/04/44972585/elon-musks-neuralink-eyes-8-5-billion-pre-money-valuation-in-latest-funding-round-report"> $8.5 billion pre-money valuation</a> in its latest round of funding as the company aims to raise over $500 million, in ongoing talks with investors.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44358022/paralyzed-man-moves-objects-with-his-mind-thanks-to-elon-musks-brain-chip">Paralyzed Man Moves Objects With His Mind—Thanks To Elon Musk&#8217;s Brain Chip</a></li>
</ul>
Image Via Shutterstock

Biotech

Tech

General

Man Battling ALS Becomes First Non-Verbal Patient To Receive Elon Musk's Neuralink Brain Implant

As AI chatbots like OpenAI's ChatGPT, Anthropic's Claude, and Perplexity reshape how users search for information, brands are adjusting their strategies to maintain visibility in this new search environment, which is increasingly displacing traditional search engines like Alphabet Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google.
What Happened: In a shift that threatens Google's dominance, brands are adopting new strategies to ensure they remain visible in the results generated by AI chatbots, <a href="https://www.ft.com/content/9cc6cc0b-759f-4b8e-9ed1-9e32ad0fe22f">reported</a> the Financial Times on Sunday.
Instead of clicking through to websites, many users now rely on AI's synthesized responses, which have decreased web traffic by up to 25%, the report noted, citing research from consultancy Bain.
Taking cognizance of this development, companies like Brandtech and Profound have developed tools that monitor how often brands appear in AI-driven responses, providing insights on how businesses can optimize for these models.
See Also: <a href="https://www.benzinga.com/25/04/44982688/alphabet-q1-earnings-preview-google-parent-stock-at-fork-in-the-road-while-antitrust-concerns-remain" target="_blank" rel="noreferrer noopener">Alphabet Q1 Earnings Preview: Google Parent Stock At ‘Fork In The Road,' While Antitrust Concerns Remain</a>
"This is about much more than just getting your website indexed in their results. This is about recognizing large language models as the ultimate influencer," said Jack Smyth, partner at Brandtech.
Brandtech has developed a &#8220;Share of Model&#8221; tool that helps brands analyze their visibility in AI search results and provides recommendations for optimizing website text and images.&nbsp;
Profound, which secured $3.5 million in seed funding in August, led by Khosla Ventures, offers a data analytics platform that enables brands to monitor popular industry queries and assess their standing within AI search results, the report said.
Why It's Important: On Thursday, Alphabet <a href="https://www.benzinga.com/25/04/44995955/alphabet-q1-earnings-highlights-google-search-youtube-cloud-show-robust-momentum">posted first-quarter revenue</a> of $90.23 billion, a 12% rise compared to the same period last year, beating Wall Street's expectation of $89.2 billion. Revenue from Google Search reached $50.7 billion, up from $46.2 billion a year earlier.
&nbsp;The strong performance helped ease investor concerns about rising competition from AI chatbots like Elon Musk's Grok and fears that Google's own Gemini chatbot and AI-generated summaries might be cutting into its traditional ad-driven search traffic, the report said.
Deepwater Asset Management's Gene Munster previously said that Google's existing search format, which blends AI overviews, blue links, and organic results, <a href="https://www.benzinga.com/25/04/44999838/can-google-adapt-like-amazon-or-will-it-face-ebays-fate-gene-munsters-candid-take-on-the-search-giants-path-forward-in-the-age-of-ai">may fall short against newer</a>, more streamlined search experiences offered by models like Grok, ChatGPT, and Claude.
Price Action: In after-hours trading, Alphabet Inc.&#8217;s Class A shares slipped 0.16% to $161.70, while Class C shares dipped 0.1% to $163.68, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Alphabet holds a growth score of 64.44%, based on Benzinga Edge Stock Rankings. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Click here to see how it compares to other companies</a> in the sector.
Photo Courtesy: Ascannio On Shutterstock.com
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44986406/if-you-invested-1000-in-google-stock-when-it-acquired-youtube-heres-how-much-youd-have-today" target="_blank" rel="noreferrer noopener">If You Invested $1,000 in Google Stock When It Acquired YouTube, Here's How Much You'd Have Today</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Media

GOOG

GOOGL

Google Faces Growing Threat As Chatbots Reshape How Users Search For Brands: Are ChatGPT, Claude And Others AI Bots Set To Be The 'Ultimate' Influencers?

Chinese manufacturers are suspending operations and pursuing alternative markets as U.S. tariff increases take effect, creating ripple effects across global supply chains and threatening millions of jobs.
What Happened: Chinese factories are pausing production due to the impact of U.S. tariffs, as <a href="https://www.cnbc.com/2025/04/28/chinese-factories-stop-production-eye-new-markets-as-us-tariffs-hit.html?ref=biztoc.com">reported</a> by CNBC on Monday. The lost orders are affecting jobs and prompting Chinese exporters to explore new sales strategies, such as livestreaming at home.
According to Cameron Johnson, a senior partner at consulting firm Tidalwave Solutions, factories producing toys, sporting goods, and low-cost Dollar Store-type goods are currently the most affected. &#8220;While not large-scale yet, it is happening in the key [export] hubs of Yiwu and Dongguan, and there is concern that it will grow,&#8221; Johnson said. The impact of recent tariff hikes exceeding 100% is &#8220;way bigger&#8221; than the COVID-19 pandemic&#8217;s disruption, says Ash Monga, CEO of Imex Sourcing Services. 
Woodswool, an athleticwear manufacturer near Shanghai, reports all U.S. orders have been canceled, with over half its production once destined for American customers. The company has pivoted to domestic sales through Baidu&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) livestreaming platform, though its new sales channel generates only modest revenue.
See Also: <a href="https://www.benzinga.com/25/04/44999959/how-the-us-china-trade-war-is-unintentionally-boosting-demand-for-intels-older-chips-amid-economic-uncertainty">Intel&#8217;s Older Parts Are In Demand Thanks To US-China Trade War: &#8216;Tariffs Have Everybody Hedging Their Bets,&#8217; Says Executive</a>
Why It Matters: Many companies are diversifying production to India over Southeast Asia, while others are turning from U.S. customers to those in Europe and Latin America. Some companies have already built businesses on other trade routes from China.
For U.S. investors, these developments signal potential disruption in supply chains and pricing. Goldman Sachs has downgraded China&#8217;s Gross Domestic Product growth <a href="https://www.benzinga.com/government/regulations/25/04/44740040/chinas-growth-outlook-dims-as-trumps-125-tariffs-put-millions-of-jobs-at-risk-goldman-warns?utm_source=chatgpt.com">forecasts to 4.0% for 2025 and 3.5% for 2026</a>, below the government&#8217;s 5% target.
The U.S.-China trade war, under President Donald Trump&#8216;s administration, has led to a <a href="https://www.benzinga.com/25/04/45026616/trumps-trade-war-causes-sharp-decline-in-us-imports-from-china">significant decrease in U.S. imports </a>from China. In response, China has started to<a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts"> exempt some U.S. imports</a> from high tariffs, indicating a possible easing of trade tensions.
The iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>), a widely followed U.S.-listed fund that tracks major Chinese companies, has fallen 4.38% since Trump introduced a 34% &#8220;reciprocal&#8221; tariff on Chinese imports.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45005825/us-has-tons-of-solutions-to-secure-rare-earth-production-if-china-halts-exports-experts-say-but-warn-of-significant-challenges">US Has &#8216;Tons Of Solutions&#8217; To Secure Rare Earth Production If China Halts Exports, Experts Say, But Warn Of Significant Challenges</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Equities

Economics

BIDU

Trump Tariffs Prompt Suspension Of Chinese Factory Operations And Shift To New Markets

<ul>
<li>Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as&nbsp;a late-breaker at the American Urologic Association annual meeting Company confirms Hugo RAS system submission to&nbsp;the U.S. Food and Drug Administration</li>
</ul>

Reported Saturday, Medtronic's Hugo RAS System Achieves 98.5% Surgical Success Rate In Largest U.S. Robotic-Assisted Urology Study

<ul>
<li>One-year clinical trial data for the next-generation, investigational, Sphere-360&#x2122; single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib</li>
<li>Dual-energy (RF/PF), focal Sphere-9&#x2122; catheter demonstrates efficacy for linear ablation in persistent AFib</li>
<li>Medtronic continues legacy of leadership in innovation, showcasing arrhythmia management portfolio at Heart Rhythm Society annual meeting</li>
</ul>

Reported Saturday, Medtronic's Affera Sphere-360 Catheter Demonstrates Safety And Performance Results For Paroxysmal AFib

Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is reportedly considering a shift of iPhone assembly to India. However, a renowned analyst has expressed skepticism about the potential effectiveness of this move in mitigating the impact of China tariffs.
What Happened: Craig Moffett, a partner and senior managing director at MoffettNathanson, questioned the feasibility of Apple&#8217;s plans on Friday. He argued that the shift to India wouldn&#8217;t significantly reduce costs related to tariffs, though it would help to some extent, as iPhone components would still be manufactured in China, <a href="https://www.cnbc.com/2025/04/26/apple-iphone-assembly-in-india-wont-cushion-china-tariffs-moffett.html">reported</a> CNBC.
&#8220;You have a tremendous menu&nbsp;of problems created by tariffs,&nbsp;and moving to India doesn&#8217;t&nbsp;solve all the problems,&#8221; Moffett told CNBC&#8217;s &#8220;Fast Money&#8221;. &nbsp;"I would question how that's going to work,&#8221; stated the analyst. 
He added that a trade war impacts both the cost of goods and demand and iPhone may face issues on the latter.
Last week, in a note to clients, MoffettNathanson reasoned that India has enough capacity to fulfill up to half of the U.S. demand for iPhones. Moreover, as the parts would still be from China, there remains an uncertainty over whether the iPhones would face Indian or Chinese tariff rates — or possibly an expensive mix of both.
Moffett told CNBC that the backlash against Apple in China, triggered by U.S. tariffs, will negatively impact iPhone sales. "Volumes are really going to the Huaweis and the Vivos and the local competitors in China rather than to Apple,&#8221; stated the analyst. 
Moffett points out that Apple also isn't receiving support from its carriers AT&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>), Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), and T. Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) to help soften the impact of tariffs, after they declared that they won&#8217;t be absorbing the additional costs of tariffs on handsets.
Moffett slashed his price target on Apple stock on Apr 21 to $141 from $184 a share.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/45029504/elon-musks-ex-wives-missed-out-on-his-billion-dollar-wealth-heres-why" target="_blank" rel="noreferrer noopener">Elon Musk's Ex-Wives Missed Out on His Billion-Dollar Wealth — Here's Why &#8211; Benzinga</a>
Why It Matters: This skepticism on the heels of previous week&#8217;s report that&nbsp;Apple plans to import most of the iPhones&nbsp;it sells in the U.S. <a href="https://www.benzinga.com/25/04/45014074/apple-plans-iphone-shift-from-china-to-india-amid-tariff-pressures-geopolitical-risks">from India</a> by the end of 2026. This would require the company to double its annual iPhone output in India to over 80 million units.
UBS analyst David Vogt <a href="https://www.benzinga.com/25/04/44973883/analysts-slash-aapl-stock-price-target-amid-anticipated-tariffs-supply-chain-concerns-a-lose-lose-choice">lowered his price target&nbsp;</a>for Apple from $236 to $210 in anticipation of widespread tariffs. Vogt noted that Apple seemed to have expedited the shipment of around one million iPhones, leading to a year-over-year rise in iPhone revenue for the March quarter.
That being said, Moffett is not completely bearish on the iPhone maker. "I think quite highly of Apple. My concern about Apple has been the valuation more than the company."
Benzinga&#8217;s Edge Rankings&nbsp;highlight strong momentum and quality rankings for Apple in the 76th and 85th percentiles, respectively. Curious how other stocks stack up?&nbsp;<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound" target="_blank" rel="noreferrer noopener">Click here</a>&nbsp;to uncover growth and momentum scores for top stocks.
Over the past month, Apple stock declined nearly 4%, as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/45017261/bitcoin-mining-costs-jump-to-137000-per-coin-when-accounting-for-non-cash-expenses-coinshares" target="_blank" rel="noreferrer noopener">Bitcoin Mining Costs Jump To $137,000 Per Coin When Accounting For Non-Cash Expenses: CoinShares &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

AAPL

TMUS

Analyst Casts Doubt On Apple's Reported Move To Shift iPhone Production To India Amid Rising China Tariff Pressures: 'Doesn't Solve All The Problems'

<ul>
<li>KEYNOTE-689 marks the first positive trial in more than two decades for patients with resected locally advanced head and neck squamous cell carcinoma (LA-HNSCC)</li>
<li>Results to be presented at American Association for Cancer Research (AACR) Annual Meeting 2025 during a Plenary Session and included in official meeting press program</li>
</ul>

Reported Sunday, Merck's Phase 3 KEYNOTE-689 Data Shows KEYTRUDA Significantly Improves Event-Free Survival As Perioperative Therapy In Locally Advanced Head And Neck Cancer

The Nasdaq has staged a remarkable turnaround in April, transforming from what was initially dubbed the &#8220;worst April for the stock market since the Great Depression&#8221; to posting gains for the month, a recovery that&#8217;s drawing attention from prominent market analysts.
What Happened: On Sunday, Tom Lee, Head of Research at Fundstrat Global Advisors, endorsed Treasury Secretary Scott Bessent&#8216;s observation about the market&#8217;s resilience, describing the equity recovery as a &#8220;White House put&#8221; – suggesting government policies are providing a floor for market values.
&#8220;Equity recovery cannot be ignored,&#8221; Lee wrote on X, responding to Bessent&#8217;s post highlighting the dramatic shift in market narrative.
The S&amp;P 500 index, tracked by SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), has gained 10.89% since its April 8 low of 4,982, currently trading around 5,525. This recovery follows concerns over potential tariff impacts and recession risks that had previously shaken investors. Meanwhile, the Nasdaq 100, tracked by Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), has surged 13.70% from its low of 17,090 on the same day, now trading at 19,432.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f440;&#x1f440;&#x1f440; &#x1f447; Agree &#x1f4af;&#x1f4af;&#x1f4af;&#x1f4af; Equity recovery cannot be ignored PS: This is also known as a "White House" put<a href="https://twitter.com/hashtag/sundayvibes?src=hash&amp;ref_src=twsrc%5Etfw">#sundayvibes</a> <a href="https://t.co/5rXpcLFYHb">https://t.co/5rXpcLFYHb</a>
&mdash; Thomas (Tom) Lee (not drummer) FSInsight.com (@fundstrat) <a href="https://twitter.com/fundstrat/status/1916562502281810374?ref_src=twsrc%5Etfw">April 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The rebound contrasts sharply with warnings from analysts like Chris Senyek of Wolfe Research, who recently cautioned that the S&amp;P 500 could plunge as low as 3,700 points – a potential 37% decline from January levels – if tariff-related uncertainty <a href="https://www.benzinga.com/markets/equities/25/04/45004528/sp-500-could-crash-37-to-3700-if-tariff-fallout-triggers-recession-warns-wolfe-research">triggers a recession in 2025</a>.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/45031324/bitcoin-ethereum-dogecoin-drop-as-stock-futures-slide-willy-woo-says-all-dips-are-for-buying-with-btc-eyeing-all-time-highs">Bitcoin, Ethereum, Dogecoin Drop As Stock Futures Slide: Willy Woo Says &#8216;All Dips Are For Buying&#8217; With BTC Eyeing &#8216;All-Time Highs</a>
Why It Matters: Market volatility has been exacerbated by President Donald Trump&#8216;s tariff announcements in early April, particularly regarding China. Despite the president&#8217;s recent statements that he would maintain tariffs without &#8220;substantial&#8221; concessions from Beijing, markets have shown surprising resilience.
Technical analysts remain cautious about the sustainability of the recovery. JPMorgan&#8216;s Jason Hunter has identified the 5,425-5,650 range as key resistance for the S&amp;P 500, <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/45011336/sp-500-magnificent-7-hit-resistance-analyst-warns-of-more-pain-before-gain">suggesting the index could retreat to 4,500-4,800</a> before establishing a &#8220;more durable bottom.&#8221;
The &#8220;Magnificent 7&#8221; tech stocks that have driven much of the market&#8217;s performance in recent years are &#8220;consolidating within volatile ranges below their respective breakdown levels,&#8221; according to Hunter, indicating <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/45011336/sp-500-magnificent-7-hit-resistance-analyst-warns-of-more-pain-before-gain">potential challenges ahead for market leaders</a> including Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Photo: JHVEPhoto / Shuttesstock
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45030669/chamath-palihapitiya-says-nvidia-is-huaweis-new-target-a-national-champion-that-crushed-tech-giants-with-a-low-end-disruptor-strategy">Chamath Palihapitiya Says Nvidia Is Huawei&#8217;s &#8216;New Target&#8217; — A &#8216;National Champion&#8217; That Crushed Tech Giants With A &#8216;Low-End Disruptor&#8217; Strategy</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

MSFT

NVDA

Tom Lee Backs Scott Bessent 'White House Put' Theory As Nasdaq Flips From Worst April Start Since Great Depression To Major Comeback

Tesla Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Chinese division is developing an affordable version of the popular Model Y crossover SUV.
What Happened: The model, dubbed the ‘E80,' will reportedly be a toned-down version of the new Model Y and feature a 50-55 kWh battery, smaller wheels, fabric seats with no ventilation, and no rear display, among other omissions, <a href="https://www.teslarati.com/tesla-china-affordable-model-y-e80-price-features-more/">notes</a> Teslarati in a report published on Sunday.
The model could be released in the latter half of 2025 or sometime in 2026, but it could also depend on how the new Model Y performs in China, the report suggests.
As for the pricing, the new variant could be offered for around CNY 150,000-210,000 or $20,500-$28,800.
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: The news comes in as Elon Musk's EV giant had shared plans to release <a href="https://www.benzinga.com/25/04/44942792/tesla-q1-earnings-call-company-says-more-affordable-models-launching-this-year">more affordable models</a> this year at the company's Q1 2025 earnings call with investors.
Tesla has already released affordable trim levels for its models before. Recently, the company released a cheaper <a href="https://www.benzinga.com/markets/equities/25/04/44755221/tesla-unveils-new-cybertruck-long-range-trim-with-a-362-mile-range-and-reduced-features">RWD LR (Long Range) version</a> with fewer features and even altered the marketing strategy for the vehicle to focus on its utilitarian properties.
The company also recently <a href="https://www.benzinga.com/tech/25/04/45004433/tesla-rolls-out-free-fsd-transfers-on-all-us-models-including-cybertruck-amid-poor-sales">announced new promotions </a>for its entire line-up in the U.S., including free FSD transfers, amid declining sales figures, as well as <a href="https://www.benzinga.com/25/04/45002083/court-documents-reveal-charges-filed-against-dc-tesla-vandalism-suspect-report">increased hostility </a>towards Musk's businesses.
Price Action: TSLA currently trades for $284.95 on the NASDAQ, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/45029648/tesla-stock-skyrockets-20-following-elon-musks-return-and-shift-from-doge">Tesla Stock Skyrockets 20% Following Elon Musk&#8217;s Return and Shift From DOGE&nbsp;</a></li>
</ul>
Image Via Shutterstock

Asia

TSLA

Tesla Reportedly Developing A Cheaper Model Y 'E80' Variant With Fewer Features In China

SWTX

Reported Sunday, SpringWorks Anticipates EMA CHMP Ruling On Nirogacestat For Desmoid Tumor Therapy In Q2 2025

Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) –
– Planned acquisition will immediately add revenue and accelerate mid- to long-term growth for Merck KGaA, Darmstadt, Germany's Healthcare business –
– SpringWorks Therapeutics is a U.S. biopharmaceutical company with a first-in-class, systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas –
– Planned acquisition will strengthen the presence of Merck KGaA, Darmstadt, Germany's Healthcare business in the United States and expand reach of SpringWorks' therapeutic innovations to more patients with rare tumors worldwide –

MKKGY

SpringWorks Therapeutics To Be Acquired by Merck KGaA, In $3.9B Deal To Expand Rare Tumor Portfolio

<ul>
<li>VYVGART&#xAE; is first-and-only targeted IgG Fc-antibody fragment for CIDP</li>
<li>First novel mechanism of action for CIDP treatment in more than 30 years</li>
<li>CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial</li>
<li>European Commission (EC) decision on marketing authorization application (MAA)&nbsp;expected within approximately two months</li>
</ul>

ARGX

argenx's VYVGART For CIDP Gains Positive CHMP Opinion Based On Data From ADHERE Clinical Trial

RVMD

Reported Sunday, Revolution Medicines Initial Phase 1 Study Data Show Zoldonrasib Achieves 61% Objective Response Rate in KRAS G12D Mutant NSCLC

Ace investor and fund manager, Cathie Wood, is doubling down on Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), reaffirming her confidence in the company's ability to lead the enterprise AI race, as shifting market dynamics disrupt established players in this space.
What Happened: On Saturday, the Ark Invest CEO quoted a post on X by Brett Winton, the firm's chief futurist, who simply wrote, "Excel. Will. Die." The post predicts the eventual downfall of Microsoft Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) widely used spreadsheet software, which has been a mainstay in office environments for decades.
See More: <a href="https://www.benzinga.com/news/25/04/45019174/palantir-stock-soars-on-defense-deals-whats-going-on">Palantir Stock Soars On Defense Deals: What&#8217;s Going On?</a>
In response to the post, Wood questioned how Microsoft and its enterprise clients would navigate the &#8220;massive disruption,&#8221; before saying, &#8220;Palantir comes to mind.&#8221; 
According to Wood, Palantir CEO Alex Karp believes that the company will become the largest pure-play enterprise AI software company in the world, &#8220;I believe him,&#8221; she says.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I wonder how <a href="https://twitter.com/search?q=%24MSFT&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$MSFT</a> and its enterprise clients are going to manage through this massive disruption. Palantir comes to mind. CEO Alex Karp believes that <a href="https://twitter.com/search?q=%24PLTR&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PLTR</a> will become the largest pure play enterprise AI software company in the world. I believe him. <a href="https://t.co/pFJxPueKdn">https://t.co/pFJxPueKdn</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1916166595593805966?ref_src=twsrc%5Etfw">April 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Palantir is now Ark Invest's <a href="https://cathiesark.com/ark-funds-combined/complete-holdings">second-largest holding</a> after Tesla, with a stake valued at $640 million, representing about 7% of its total assets under management across its family of funds.
Microsoft has made significant headway in enterprise AI, with the segment already sporting a <a href="https://benzinga.com/markets/equities/25/01/43327008/microsofts-13-billion-run-rate-and-openai-azure-deal-spark-surge-in-enterprise-demand-for-ai-solutions-just-first-tranche-of-future-growth-potential">$13 billion annual run rate</a>, a figure that is nearly 5 times Palantir&#8217;s annual revenue in 2024. However, the latter is gaining ground rather quickly and is already pulling ahead in sectors such as defense. 
While Microsoft continues to pursue cloud dominance, <a href="https://benzinga.com/trading-ideas/technicals/25/04/44947382/palantir-rolls-out-tanks-microsoft-builds-clouds-whos-winning-ais-next-frontier">Palantir is inking partnerships</a> with major defense contractors and is in the process of building a futuristic AI-powered tank. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Stock / ETF</td>
<td class="has-text-align-center" data-align="center">YTD Performance</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</td>
<td class="has-text-align-center" data-align="center">-6.39%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)</td>
<td class="has-text-align-center" data-align="center">+49.99%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Ark Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>)</td>
<td class="has-text-align-center" data-align="center">-10.35%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Ark Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>)</td>
<td class="has-text-align-center" data-align="center">-4.89%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="141" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM-1024x141.png" alt="" class="wp-image-890106" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM-1024x141.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM-300x41.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM-768x106.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM-1536x211.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28012832/Screenshot-2025-04-28-at-10.58.18-AM.png 1616w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Palantir scores remarkably well on Benzinga&#8217;s Stock Edge Rankings, with a strong price trend in the short, medium, and long terms, but how does it compare with Microsoft? Sign up for <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Benzinga Edge</a> to find out.
Photo courtesy: slyellow / Shutterstock.com
Read More: <a href="https://www.benzinga.com/25/04/45031447/elon-musk-says-the-best-human-surgeons-have-just-five-years-before-robots-overtake-them-reveals-instance-when-neuralink-had-to-use-a-robot-for-task-impossible-for-a-human">Elon Musk Says Best Human Surgeons Will Be Outdone By Robots In Almost 5 Years, Cites Example Of His Own Brain-Chip Company</a>

ETFs

ARKK

ARKX

PLTR

Cathie Wood Sees Palantir Dominating Enterprise AI, Wonders How Microsoft Will Manage 'Massive Disruption' — Will Excel Finally Die?

Press Releases

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Contracts

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex to Participate at BIO Europe Spring 2025

CS Diagnostics (OTCQB: CSDX) CS-Protect Hydrogel FDA Approval on Fasttrack – GNPX, BON, SES, BETRF – Stocks to Watch Now!

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

BETRF

CSDX

CSE:BETR

GNPX

Aditxt

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Entero Therapeutics

GRI Bio

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Synaptogenix

Tharimmune

VivoSim Labs

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Genprex

Genprex (GNPX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO